INGELHEIM & JENA, Germany - Monday, 02. October 2023
(BUSINESS
WIRE)--Boehringer Ingelheim and ZEISS Medical Technology announce today
a long-term strategic collaboration to develop predictive analytics to
enable early detection of eye diseases and prevent vision loss for
people with serious eye diseases. The partnership brings together their
leading expertise in ophthalmological technology, data analytics,
algorithms, and the development of treatments to detect early and treat
retinal diseases before irreversible loss of vision occurs.
More
than 300 million people worldwide are at risk today of losing their
eyesight due to diseases leading to functional loss of the retina.* The
number of people suffering from vision loss is expected to rise due to
aging populations and widening health inequity gaps. Undiagnosed and
untreated retinal diseases can have a profound impact on people’s lives,
potentially leading to isolation, loss of independence, depression, and
reduced quality of life. Unfortunately, diagnosis often occurs too late
to prevent vision loss, and for many conditions, no treatment is
available at all.
The new partnership will focus on identifying
markers of early stages of retinal diseases by leveraging ZEISS Medical
Technology’s cloud-connected devices and AI-assisted analysis of its
extensive image data sets. This will provide a basis for clinical
studies for development of more personalized and precise treatments of
early stages of chronic retinal disease as well as earlier detection and
prediction capabilities to preserve vision through new treatment
pathways.
“At ZEISS, we have long understood that where
collaboration thrives, innovation emerges,“ said Euan S. Thomson, Head
of the Ophthalmology Strategic Business Unit and Head of the Digital
Business Unit for ZEISS Medical Technology. “With our announcement today
with Boehringer Ingelheim, we’re building on our strategy to innovate
through partnerships in order to make breakthrough discoveries to combat
vision loss and improve people’s lives.”
“Our partnership with
ZEISS will allow us to develop precision therapies delivering the right
treatment for the right patient at the right time to prevent vision loss
by intervening before irreversible damage occurs. It is part of our
commitment to champion early detection and treatment and will contribute
to transforming the lives of people with serious eye disease,” said
Ulrike Graefe-Mody, Ph.D., Head of Retinal Health at Boehringer
Ingelheim.
As a leading pioneer of science in optics for more
than 100 years, ZEISS’s medical expertise and digital leadership is
foundational to the ZEISS Medical Ecosystem and its digitally connected
workflows. This connected and secure architecture integrates diagnostic
and therapeutic devices supported by a cloud-based platform in which
data aggregation, automation and AI analytics can be harnessed to drive
new discoveries.
Boehringer Ingelheim has a leading understanding
of disease biology aiming at a paradigm change in retinal health
through early detection and intervention to achieve meaningful
improvements for patients. Over the past decade Boehringer Ingelheim has
built a diverse pipeline, which focuses on three priority areas to
address retinal conditions – the preservation of vascular function,
targeting inflammation and neuroprotection.
Click here for the
full
release:https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-and-zeiss-partnership-eye-diseases?auHash=n2thfphi3cpKoj_GxyxhoWGqmhRDlOzIYhDvK5zfYMg
References
*
World Health Organization, World Report on Vision, Executive Summary,
October 8, 2019,
https://www.who.int/publications/i/item/world-report-on-vision
View source version on businesswire.com: https://www.businesswire.com/news/home/20231002790283/en/
Permalink
https://www.aetoswire.com/en/news/2102023347411
Contacts
Harro Ten Wolde
Head of Global Media Relations
Email: harro.ten_wolde@boehringer-ingelheim.com
Phone Number: +49 (6132) 77-181352
No comments:
Post a Comment